Tarsus Pharmaceuticals (TARS) FCF Margin (2021 - 2026)

Tarsus Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 15.77% for Q1 2026.

• On a quarterly basis, FCF Margin rose 1134.0% year-over-year to 15.77% in Q1 2026; TTM through Mar 2026 was 4.98%, a 2407.0% increase from a year earlier, with the FY2025 full-year figure at 4.94%, up 4130.0% from the prior year.
• FCF Margin slipped to 15.77% in Q1 2026 per TARS's latest filing, from 7.23% in the prior quarter.
• Across five years, FCF Margin topped out at 15.46% in Q3 2025 and bottomed at 2865.86% in Q1 2022.
• The 5-year median for FCF Margin is 33.42% (2024), against an average of 416.61%.
• Biggest YoY gain for FCF Margin was 332891 bps in 2022; the steepest drop was 282683 bps in 2022.
• Year by year, FCF Margin stood at 110.14% in 2022, then plunged by 168 bps to 294.82% in 2023, then surged by 88 bps to 35.67% in 2024, then surged by 120 bps to 7.23% in 2025, then tumbled by 318 bps to 15.77% in 2026.
• Per Business Quant, the three latest TARS FCF Margin figures stand at 15.77% (Q1 2026), 7.23% (Q4 2025), and 15.46% (Q3 2025).